Carolyn Fairbanks


Carolyn Fairbanks, Ph.D.

Academic Title

Associate Professor
Pharmaceutics

Education

Bachelor's
Biology, 1991, Macalester College
Ph.D.
Pharmacology, 2000, University of Minnesota

Contact Info

Email
carfair@umn.edu

Phone
612-625-2945

Fax
612-626-2125

Office Address

Room 9-143A
Weaver-Densford Hall

Mailing Address

University of Minnesota
College of Pharmacy
Department of Pharmaceutics
Room 9-177 WDH
308 Harvard St. SE
Minneapolis, MN 55455
U.S.A.

Research Interests

Department of Pharmaceutics

The spinal cord carries pain signals to the brain via excitatory neurotransmission and contains most of the same inhibitory neurotransmission systems as the brain. Spinal delivery of analgesics that activate such inhibitory systems offers a very selective method of pain control that can increase the therapeutic index of such analgesics by reducing or eliminating their exposure to brain regions that mediate undesired side effects.

Dr. Carolyn Fairbanks’ research focuses on development of novel compounds with a pharmacokinetic/dynamic profile ideal for spinal delivery for pain relief. One major focus is the continued characterization and clinical translation of a new compound, moxonidine, as well as its corresponding target, the alpha2C adrenergic receptor. The spinal cord contains alpha2C adrenergic receptors on intrinsic spinal neurons which, when activated by agonists such as moxonidine, inhibit action potentials that transmit the pain signal from the periphery to the brain. Dr. Fairbanks’ studies of moxonidine have used methods that incorporate the use of transgenic mice, antisense oligonucleotides and immunocytochemistry.

A second interest of Dr. Fairbanks’ team includes understanding the basic spinal neural mechanisms (glutamate-induced plasticity) governing induction chronic pain as well as opioid-induced tolerance and addiction. Her laboratory currently researches the role of an endogenous amine, agmatine (decarboxylated arginine), in those biological events. Studies of glutamatergic and agmatinergic neurotransmission in the spinal cord apply behavioral, biochemical, immunocytochemical and molecular techniques. Acquiring such information may lead to the development of a novel class of spinally delivered drugs intended for reversing (rather than alleviating) the effects of chronic pain.

  • ©2014 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on June 27, 2013